

CHANGE OF STATUS REPORT

NOTICE PURSUANT TO SECTION 11.2 OF NATIONAL INSTRUMENT 51-102 – *CONTINUOUS DISCLOSURE OBLIGATIONS*

TO: British Columbia Securities Commission
Alberta Securities Commission
Financial and Consumer Affairs Authority of Saskatchewan
Manitoba Securities Commission
Ontario Securities Commission
Financial and Consumer Services Commission, New Brunswick
Nova Scotia Securities Commission
The Office of the Superintendent Securities, Prince Edward Island
Office of the Superintendent of Securities Service Newfoundland and Labrador

RE: Bright Minds Biosciences Inc. (the “**Issuer**”) – Change of Status Report

On November 8, 2021, the Company’s common shares became listed for trading on The Nasdaq Capital Market under the trading symbol “DRUG”. The Company has also retained its listing of common shares on the Canadian Securities Exchange under the symbol “DRUG”.

As a result, on November 8, 2021, the Company ceased to be a “venture issuer” under National Instrument 51-102, *Continuous Disclosure Obligations*.

DATED this 15th day of February, 2022.

BRIGHT MINDS BIOSCIENCES INC.

By: “Ian McDonald”

Ian McDonald

Chief Executive Officer